Pro Medicus (PME) Stock Price, Fundamentals & Analysis

What PME does

Pro Medicus (PME) is a healthcare informatics company that provides medical imaging software and services to hospitals, imaging centers, and healthcare groups in Australia, Europe, and North America. Its products include Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, and integration with picture archive and communication systems (PACS); Visage 7 Enterprise Imaging Platform, which allows radiologists and clinicians to view 2-D, 3-D, and 4-D medical images; and Visage Ease, a mobile application for accessing imaging results on iOS devices. The company also offers Visage Ease Pro for diagnostic interpretation and Promedicus.net, an e-health offering. PME is part of the ASX 200 and operates in the Health Information Services industry alongside peers such as EBOS Group (EBO), Sonic Healthcare (SHL), and 4DMedical (4DX).

Key numbers explained

• 161 AUD is the current share price, the amount you would pay for one share on the ASX.
• The trailing P/E ratio of 63.4 compares the share price to the last 12 months of earnings per share (2.54 AUD); a higher number can indicate the market expects strong future growth.
• The forward P/E ratio of 70.5 uses expected future earnings, showing how the market values what the company may earn next.
• Dividend yield of 0.43% shows the annual dividend as a percentage of the share price; the ex-dividend date is 7 Sept. 2026.
• Beta of 0.58 suggests the stock tends to move less than the overall market, often viewed as lower volatility.
• 16.82 mld. AUD is the market capitalisation, the total value of all outstanding shares.
• Price-to-book of 37.3 compares the share price to the company's book value per share, often used to assess whether the market prices the company above its accounting net assets.
• The 52-week range of 107,75 – 316,26 shows the lowest and highest traded prices over the past year, with the current price near the lower end of that span.

What to watch

• Revenue growth of 18.2% year over year and a profit margin of 101.4% are unusual and worth understanding in context, as they reflect specific accounting and business model factors.
• The operating margin of 77% and return on equity of 75% indicate strong profitability relative to revenue and shareholder capital.
• The debt-to-equity ratio of 0.5 shows the company uses some debt but maintains a conservative capital structure.
• The price change over the last 52 weeks of -46.6% highlights the importance of looking at longer-term trends rather than short-term moves.
• The next earnings release is scheduled for 18 Aug. 2026, a common catalyst for price movement.
• Investors often compare PME with other healthcare IT and services companies such as Cochlear (COH), Ramsay Health Care (RHC), and Sigma Healthcare (SIG) to understand sector positioning.